Revolution Medicines Inc

Historic regulatory + guideline momentum for RAS(ON)Q (daraxonrasib) in metastatic pancreatic cancer - US FDA approval on Aug 26, 2026 for adults with metastatic pancreatic adenocarcinoma after ≥1 prior systemic therapy (or not candidates for multi-agent systemic therapy). - NCCN guideline expansion: Ras(ON)Q moved into Category 1 preferred subsequent therapy for appropriate patients after prior systemic therapy (including *locally advanced and recurrent* disease), and also listed for certain first-line metastatic scenarios (with category linked to performance-status assessment). - Other regulatory signals: - FDA Breakthrough Therapy designation for RAS(ON)Q + gemcitabine + nab-paclitaxel in first-line metastatic pancreatic cancer. - EMA CHMP positive opinion (monotherapy label for post–prior systemic therapy metastatic pancreatic cancer), pending final European Commission decision. - Implication/opportunity: strong external validation beyond the initial label; supports uptake and longer-term positioning as a potential standard of care.

Early US commercial performance (only ~5 weeks post-approval) shows strong initial demand, but sustainability uncertainty remains - Q3 net product revenue: $198M (partial quarter + includes initial channel stocking). - Commercial patients treated: >5,000 unique patients on commercial basis in the quarter. - Channel inventory: ended quarter with <2 weeks supply; company targets ~2 weeks long-term. - Demand drivers (management framing): 1) EAP-to-commercial transition (now complete for ongoing patients). 2) Patients who had exhausted available therapies and were waiting for an approved option (finite early cohort). 3) Newly eligible patients initiating treatment after approval (this cohort is the more “normalized” demand path). - Key “good but cautious” takeaway: management is encouraged, but explicitly says it’s too early to judge the normalized launch trajectory because cohorts (1) and (2) are finite.

Commercial readiness + payer access progress (mostly positive early) - Physician engagement reported as broad across academic and community oncology. - Provider mix: ~2.7k unique prescribers; ~40% academic / ~60% community (representative of patient volume). - Payer coverage: strong early functional access; claims reimbursed across plans covering >90% of US PDAC lives. Formal coverage policies are still developing for many plans (expected given early stage). - Support infrastructure: patient access services fully operational (benefits verification, coverage navigation, financial assistance, patient support). - Tolerability feedback: early experience described as “very positive” with emphasis on education/prophylaxis/management; company did not provide detailed rates and noted it is very early.